Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

in moderately to severely active CD and UC patients, who had failed at least one conventional or anti-TNFα therapy.

"With a targeted mechanism of action, vedolizumab has clinical promise as a potential treatment option for people with moderate to severely active CD and UC," said Paul Rutgeerts, M.D., Ph.D., F.R.C.P., professor of medicine, Catholic University of Leuven, Belgium. "While there is no known cure, there is a need for new CD and UC treatment options, in an effort to provide patients with additional choices for managing their disease, reducing symptoms and achieving remission."

About Crohn's disease and ulcerative colitis

Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the lining of the GI tract. CD can impact any part of the digestive tract, and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and/or fever. UC impacts the large intestine only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction of an outside agent, such as a virus or bacteria, with the body's immune system may trigger them. No cure exists for CD or UC; the aim of IBD treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab

Vedolizumab was developed for the treatment of CD and UC, as a gut-selective, humanized monoclonal antibody that specifically antagonizes the alpha4beta7 (α4β7) integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. α4β7 binds with a specific adhesion molecule primarily expressed in the intestinal tract. Ther
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Improved Long-term [Five-years],Overall Survival for these Seriously ... -- FOLFOX4, an,Eloxatin(R)-based chemotherapy regimen, provided significant,improvements ... and,time to disease progression (TTP) - a ... with metastatic (advanced) colorectal cancer.,Importantly, the FOLFOX4 ...
... Presented at Society of Nuclear,Medicine Annual Meeting ... Inc. , a biopharmaceutical company focused on,developing ... serious,diseases, today announced that its anti-carcinoembryonic antigen,(CEA) ... found to be safe and active when ...
Cached Medicine Technology:Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 2Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 3Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... ... for the treatment of acute injuries and chronic conditions affecting soft tissues, such as ... ... Therapy, a leading provider of physical medicine and rehabilitation services in the metropolitan New ...
... Arizona criminal attorney ... case of State v. Norton. The Downtown Justice Court suppressed Norton,s breath alcohol readings of ... Phoenix, ... was able to get the breath alcohol readings suppressed in the case of State V. ...
... Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month: , ... , , ... ... "BHR Pharma ...
... March 23 Healthcare organizations looking to reduce costs and improve patient care by extending their information management to the mobile world can now do so without undergoing ... ... ... ...
... secure and trusted environment using MobiSecure® SMS, a new product introduced today by Diversinet Corp. (OTC Bulletin Board: DVNTF; TSX Venture: DIV). , ... , ... ... ...
... be harder to lie about your age or your poker ... has revealed that our eye position betrays the numbers we ... asked to state a series of random numbers. By measuring ... predict with reliable confidence the next chosen number - before ...
Cached Medicine News:Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 2Health News:New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury 3Health News:Arizona Criminal Attorney Gets Breath Alcohol Readings Suppressed 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 2Health News:BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 2Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 3Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 4Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 5Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 6Health News:Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations 7Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 2Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 3Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 4Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 5Health News:Diversinet's New MobiSecure(R) SMS Provides Healthcare Organizations With Secure and Protected SMS Communications 6Health News:Our eye position betrays the numbers we have in mind, new study 2
This legless table has adjustable height and round post. Pad sold separately....
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
This table has adjustable height, round post, and universal clamp. Replacement 1" (5 cm) or 2" (2.5 cm) pad sold separately....
... An excellent choice for orthopedic procedures. ... width to 24" for the ... clamps quickly attach to any O.R. ... easy C-Arm access and stability. ...
Medicine Products: